Unlocking the Potential of Biosimilars in Community Oncology
Today, biologics make up more than half of the oncologic therapies in the pipeline. These pioneering therapies now allow more than 350 million patients with cancer globally to receive their treatment through a painless injection rather than an 8-hour chemotherapy session.1
But, bringing innovation to patients with groundbreaking therapies can be a time intensive, intricate, confusing, and expensive process.
For the full article, visit Cancer Therapy Advisor.